Ivonescimab with or without chemo for advanced NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-squamous non-small cell lung cancer that cannot be treated with surgery or radiation.
- Your cancer must have one of these genetic changes: EGFR mutation, or ALK, ROS1, RET, or NTRK fusion.
- You need to have tried at least one targeted therapy pill for your specific mutation, and possibly chemotherapy, depending on the study group.
- You must be willing to have a biopsy before and during the study (sometimes old samples can be used).
- Your overall health should be good (ECOG 0 or 1) and you must be at least 18 years old.
- You cannot have had immunotherapy or certain other treatments in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.